All In Biotech

NDA 207964 · Medline Industries

Readyprep Chg

Chlorhexidine Gluconate · Topical

Last checked: Nov 20, 2026Latest source record: May 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 20, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

551

112 Phase 3, 30 recruiting

FAERS reports

66

37 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 9, 2024.

Uses helps reduce bacteria that can potentially cause skin infection for preparation of skin prior to surgery

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 20, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • READYPREP CHG · CHLORHEXIDINE GLUCONATE 2% · CLOTH, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorhexidine Gluconate" as an intervention, any sponsor and status, largest first.

All 551 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash20
  • skin reaction12
  • erythema9
  • pruritus4
  • skin irritation4
  • sepsis3
  • burkholderia infection2
  • eye irritation2
  • hypersensitivity2
  • pain2
  • sputum culture positive2
  • ageusia1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20163
20174
20192
20201
20215
20221
202319
202410
202512
20269

Recalls

1 FDA enforcement reports for this application.

  • May 14, 2021 · Class III · Terminated

    Superpotent Drug: Product is above specification for active ingredient, 2% Chlorhexidine Gluconate.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 571 on PubMed

Sponsor: Medline Industries

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.